EJINE OKOROAFOR: Open Payments
NPI 1003164377 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,953 in 132 payments from 15 companies in 2025. Trend: 2023 $1,758 · 2024 $2,479 · 2025 $2,953
Food & beverage: $2,953
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 18 | $478 |
| Alkermes, Inc. | 18 | $432 |
| Otsuka America Pharmaceutical, Inc. | 18 | $353 |
| ABBVIE INC. | 14 | $302 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $241 |
| E.R. Squibb & Sons, L.L.C. | 13 | $235 |
| Vanda Pharmaceuticals Inc. | 8 | $212 |
| Lundbeck LLC | 10 | $202 |
| Axsome Therapeutics, Inc. | 8 | $143 |
| Almatica Pharma LLC | 6 | $141 |
Products named: INGREZZA, REXULTI, ARISTADA, VRAYLAR, CAPLYTA, COBENFY, FANAPT, Auvelity.
Industry payments across NV — which companies pay providers there.
